First Manhattan
CASC

First Manhattan’s Cascadian Therapeutics, Inc. CASC Stock Holding History

First Manhattan’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-83
Closed -$1K – 1505
2014
Q2 		$1K Hold
83
– – ﹤0.01% 1390
2014
Q1 		$1K Sell
83
-86,400
-100% -$1.42M ﹤0.01% 1379
2013
Q4 		$913K Sell
86,483
-234,800
-73% -$2.62M 0.01% 432
2013
Q3 		$3.97M Hold
321,283
– – 0.03% 251
2013
Q2 		$3.06M Buy
+321,283
New +$4.13M 0.02% 281

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

First Manhattan's CASC Position: Q3 2014 in Review

First Manhattan sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2014, closing a stake of 83 shares — an estimated $1K sold.

First Manhattan first reported a position in CASC in Q2 2013 and held it in 5 quarters. The position peaked at $3.97M in Q3 2013. 86 funds tracked by Wall St. Rank hold CASC as of Q3 2014.

  • First Manhattan reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • First Manhattan sold 83 Cascadian Therapeutics, Inc. shares in Q3 2014, an estimated $1K.
  • First Manhattan first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
  • First Manhattan's Cascadian Therapeutics, Inc. position peaked at $3.97M in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2014.

Based on First Manhattan's 13F filing for Q3 2014, filed 23 Oct 2014.